News Sentiment

IPHA sentiment intelligence

Innate Pharma news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.79 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

77/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-0.4% over one week, +1.8% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Innate Pharma (IPHA) Edges Higher Near Key Support; Resistance at $1.88 in Focus - Breakaway Gap

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 77/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend active 1.8% over four weeks
Fair value -16.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 40
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
TradingKey 6
Market source 5
TradingView 5
MarketBeat 3
dars.gov.et 2
DonanımHaber 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 17
Analyst action 2
Guidance 2
Regulatory and legal 1
Macro sensitivity 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Insider Monkey Direct company coverage

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript

Innate Pharma S.A. held its Q1 2026 earnings call, exceeding EPS expectations. The company provided updates on its key pipeline assets: lacutamab, IPH4502, and partnered programs with AstraZeneca (monalizumab and IPH5201). Important upcoming milestones include the initiation of t

Tone
Positive 67/100
Event
Earnings
Published
14 May 2026 12:38
Source
Insider Monkey
Stock Titan Direct company coverage

IPHYF SEC Filings - Innate Pharma Marseille 10-K, 10-Q, 8-K Forms

This article provides an overview of Innate Pharma S.A.'s (IPHYF) SEC filings, including 10-K, 10-Q, and 8-K forms, which detail the company's financial performance, oncology pipeline, and strategic collaborations. Recent filings highlight a 2025 net loss of €49.2 million with si

Tone
Negative 32/100
Event
Market update
Published
14 May 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

Innate Pharma (Nasdaq: IPHA) details Q1 2026 cash runway and trial plans

Innate Pharma reported its Q1 2026 business update, highlighting plans for the TELLOMAK-3 confirmatory Phase 3 trial for lacutamab, contingent on non-dilutive financing. The company also provided updates on other pipeline assets, including IPH4502 and IPH5201, while noting its ca

Tone
Neutral 50/100
Event
Balance sheet
Published
13 May 2026 12:09
Source
Stock Titan
Quantisnow Direct company coverage

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

Quantisnow published a press release detailing the number of shares and voting rights for Innate Pharma S.A. (IPHA) as of April 16, 2026. Quantisnow Plus members received an alert about this publication almost immediately after it was released. The platform provides real-time mar

Tone
Neutral 50/100
Event
Market update
Published
12 May 2026 17:09
Source
Quantisnow